Reviewer’s report

Title: Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in the elderly in Poland

Version: 1  Date: 23 June 2012

Reviewer: José Pedro L. Nunes

Reviewer’s report:

General comments - The manuscript entitled “Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in the elderly in Poland” is an interesting report, with mainly epidemiological interest. The findings and conclusions of the paper are of course limited to Poland, since the pattern of prescription in this country may differ significantly from other countries.

The paper is well prepared and no major problems were found: 1) The question posed by the authors is well defined. 2) The methods are appropriate and well described. 3) The data seem to be sound. 4) The manuscript adheres to the relevant standards for reporting and data deposition. 5) The discussion and conclusions are well balanced and adequately supported by the data. 6) The limitations of the work are clearly stated. 7) The authors clearly acknowledge the work upon which they are building (Ref. 11). 8) The title and abstract convey accurately what has been found.

Concerning the writing, it is acceptable overall, but the English writing could be clearly improved.

Minor essential revisions – could the authors change:

Abstract, line 8, “with the average age”

Introduction, second paragraph, “The antithrombotic effect of ASA” (instead of anticoagulant – ASA is usually not considered to have anticoagulant effects)

Material and Methods, line 4 – “The project was carried out” instead of “realized”

Results, line 4 – “The age difference” (add The)

Results, paragraph 5, first line “We observed” (instead of “there were observed”)  
Discussion, third page, three lines from bottom - “in primary prevention in diabetic patients” (instead of “prevention of diabetes”) – if I understood correctly, it is not diabetes that is being prevented.

Limitations – “contraindications” – spelling error

Discretionary revisions

The authors could comment on new anticoagulant drugs (e.g. dabigatran, etc.) and new antiplatelet drugs (e.g. ticagrelor, etc.), if only to mention that were not in use in Poland.
Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:
I declare that I have no competing interests